28279-52-9 Usage
Description
1H-Imidazo[4,5-b]pyridine,5-bromo-(8CI) is a heterocyclic organic compound characterized by its unique chemical structure and properties. It is a reagent with significant potential in the field of pharmaceuticals and biochemistry due to its ability to be used in the synthesis of various biologically active agents.
Uses
Used in Pharmaceutical Industry:
1H-Imidazo[4,5-b]pyridine,5-bromo-(8CI) is used as a key intermediate in the synthesis of prolyl-tRNA synthetase inhibitors. These inhibitors play a crucial role in the treatment of inflammatory diseases by targeting and modulating the activity of prolyl-tRNA synthetase, an enzyme involved in protein synthesis and inflammation regulation.
Used in Research and Development:
In addition to its pharmaceutical applications, 1H-Imidazo[4,5-b]pyridine,5-bromo-(8CI) is also utilized in research and development for the creation of novel compounds with potential therapeutic properties. Its unique structure allows for the exploration of new chemical pathways and the development of innovative drugs for various medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 28279-52-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,2,7 and 9 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 28279-52:
(7*2)+(6*8)+(5*2)+(4*7)+(3*9)+(2*5)+(1*2)=139
139 % 10 = 9
So 28279-52-9 is a valid CAS Registry Number.
InChI:InChI=1/C6H4BrN3/c7-5-2-1-4-6(10-5)9-3-8-4/h1-3H,(H,8,9,10)
28279-52-9Relevant articles and documents
Synthesis, biological properties and structural study of new halogenated azolo[4,5-b]pyridines as inhibitors of CK2 kinase
Chojnacki,Lindenblatt,Wińska,Wielechowska,Toelzer,Niefind,Bretner
, (2020/12/21)
The new halogenated 1H-triazolo[4,5-b]pyridines and 1H-imidazo[4,5-b]pyridines were synthesised as analogues of known CK2 inhibitors: 4,5,6,7-tetrabromo-1H-benzotriazole (TBBt) and 4,5,6,7-tetrabromo-1H-benzimidazole (TBBi). Their influence on the activity of recombinant human CK2α, CK2α’ and PIM1 kinases was determined. The most active inhibitors were di- and trihalogenated 1H-triazolo[4,5-b]pyridines (4a, 5a and 10a) with IC50 values 2.56, 3.82 and 3.26 μM respectively for CK2α. Furthermore, effect on viability of cancer cell lines MCF-7 (human breast adenocarcinoma) and CCRF-CEM (T lymphoblast leukemia) of all final compounds was evaluated. Finally, three crystal structures of complexes of CK2α1-335 with inhibitors 4a, 5a and 10a were obtained. In addition, new protocol was used to obtain high-resolution crystal structures of CK2α’Cys336Ser in complex with four inhibitors (4a, 5a, 5b, 10a).